Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD
The Dermatology Digest
DECEMBER 15, 2023
The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.
Let's personalize your content